Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
Purpose
RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.
Condition
- Cystic Fibrosis
 
Eligibility
- Eligible Ages
 - Over 6 Years
 - Eligible Sex
 - All
 - Accepts Healthy Volunteers
 - No
 
Inclusion Criteria
RETRIAL-Mental Health: - PWCF age 6 years and up (if age is < 12 years old, the PWCF's caregiver will complete daily diaries and surveys; see "Caregiver Participant Inclusion Criteria" below) - Eligible for VTD and intending to take it - Experienced new or worsening mental health symptoms after initiating ETI, which led to one of the following changes in treatment to currently taking: 1. No modulators 2. A modulator other than ETI 3. A flipped dose of ETI 4. A reduced dose of ETI - Willing to delay first VTD dose for short period of time to complete the Baseline assessments - Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links - Is English-speaking. RETRIAL-LIVER: - A person with CF age 6 years and up - Eligible for VTD and intending to take it - Experienced drug-induced liver injury (as defined by local care team) after initiating ETI, which led to one of the following changes in treatment to currently taking: 1. no modulators; or 2. a modulator other than ETI; or 3. a reduced or altered dose of ETI; - Willing to delay first VTD dose for short period of time to complete the Baseline assessments - Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links - Is English-speaking.
Exclusion Criteria
RETRIAL-Mental Health: - Cannot access VTD - Currently, or prior history of, taking VTD - Unable or unwilling to follow protocol - If <12 years old, having another <12-year-old person in the same household consented into the study - Is actively listed on any transplant list, or within 3 months post-transplant surgery - Is currently pregnant (test not required) - Anticipated change in CF Care Centers in the next 6 months - Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. RETRIAL-LIVER: - Cannot access VTD - Currently, or prior history of, taking VTD - Unable or unwilling to follow protocol - If <12 years old, having another <12-year-old person in the same household consented into the study - Any severe, decompensated liver disease (e.g. Child-Pugh, Class C) - Is actively listed on any transplant list, or within 3 months post-transplant surgery (any organ), or history of liver transplant - Is currently pregnant (test not required) - Anticipated change in CF Care Centers in the next 6 months - Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. Caregiver Participant: Inclusion Criteria: - Is a primary, daily caregiver of a person with CF under the age of 12 enrolled in the study - Has access to smart device (phone, tablet, etc.) capable of receiving messages with survey links - Is able to read and complete surveys and Daily Diary in English. Exclusion Criteria: - Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.
Study Design
- Phase
 - Study Type
 - Observational
 - Observational Model
 - Cohort
 - Time Perspective
 - Other
 
Arm Groups
| Arm | Description | Assigned Intervention | 
|---|---|---|
| RETRIAL-Mental Health | People with CF ages 6 and up with a history of new or worsening mental health symptoms (such as depression, anxiety, mood, sleep) while on elexacaftor/tezacaftor/ivacaftor (ETI) requiring discontinuation or change from standard dosing who start taking vanzacaftor/tezacaftor/deutivacaftor (VTD). | 
                                                
  | 
                
| RETRIAL-Neuro | People with CF from RETRIAL-Mental Health who experienced new/worsening neurocognitive symptoms (such as brain fog or memory problems) while taking elexacaftor/tezacaftor/ivacaftor (ETI). | 
                                                
  | 
                
| RETRIAL-Liver | People with Cystic Fibrosis ages 6 and up with a history of drug-induced liver injury (such as elevated liver enzymes) attributed to elexacaftor/tezacaftor/ivacaftor (ETI) requiring dose modification or discontinuation who start taking vanzacaftor/tezacaftor/deutivacaftor (VTD). | 
                                                
  | 
                
Recruiting Locations
Kansas City 4273837, Kansas 4273857 66160
More Details
- Status
 - Recruiting
 - Sponsor
 - Boston Children's Hospital
 
Detailed Description
RETRIAL is a prospective, longitudinal, observational, multi-site study of people with Cystic Fibrosis (PWCF) ages 6 and up who had to either change how they took or stop taking elexacaftor/tezacaftor/ivacaftor (ETI) due to new or worsening mental health/cognitive symptoms (such as depression, anxiety, mood, sleep, and/or brain fog/memory problems) and/or liver issues (elevated liver enzymes) while taking the standard dose, and who plan to start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).